Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can remote care and pharmacists improve lupus kidney treatment?

NCT ID NCT07783152

Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study evaluates a new care model for people with lupus nephritis, a kidney complication of lupus. The approach uses telemedicine visits and clinical pharmacist practitioners to provide medication support, adherence help, and remote monitoring, with oversight from specialists. Researchers will assess whether this pathway is feasible and acceptable to patients, and explore its impact on medication adherence and clinical outcomes. About 25 adults with lupus nephritis will participate by answering surveys and taking part in an interview.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A care pathway combining telemedicine visits and clinical pharmacist practitioners to support medication adherence and monitoring.
What this could lead to
If successful, this approach could offer a more accessible and supportive way to manage lupus nephritis, potentially improving medication adherence and health outcomes.
What could go wrong
This is a small, early-stage feasibility study with only 25 participants, so results may not apply broadly. The pathway's effectiveness on clinical outcomes remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Active patient at a Duke University Health System clinic * Current diagnosis of Systemic Lupus Erythematosus (SLE) based on the 1997 ACR,32 2012 Systemic Lupus International Collaborating Clinics (SLICC),33 or 2019 European League Against Rheumatism (EULAR)/ACR (American College of Rheumatology)34 classification criteria * Aged 18 years or older * Able to provide informed consent * Able to attend telemedicine visits * New onset or ongoing active LN based on rheumatologist or nephrologist evaluation Exclusion Criteria: * Patients with severe cognitive impairment * Do not wish to receive longitudinal care at our health system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lupus nephritis (LN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lupus nephritis (LN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.